These findings provide evidence for the involvement of anti-oxLDL IgM autoantibodies in NPC1 disease progression and highlight vaccination strategies leading to the elevation of anti-oxLDL IgM titers as a promising therapeutic approach to reduce NPC1 disease symptoms. The gene discussed is CD40LG; the disease is Niemann-Pick disease, type C1.